Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 10.57
FOLD's Cash to Debt is ranked higher than
68% of the 1428 Companies
in the Global Biotechnology industry.

( Industry Median: 39.38 vs. FOLD: 10.57 )
FOLD' s 10-Year Cash to Debt Range
Min: 5.67   Max: No Debt
Current: 10.57

Equity to Asset 0.58
FOLD's Equity to Asset is ranked higher than
66% of the 1094 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. FOLD: 0.58 )
FOLD' s 10-Year Equity to Asset Range
Min: 0.36   Max: 0.84
Current: 0.58

0.36
0.84
F-Score: 4
Z-Score: 4.59
M-Score: -1.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -4438.05
FOLD's Operating margin (%) is ranked higher than
51% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -96.70 vs. FOLD: -4438.05 )
FOLD' s 10-Year Operating margin (%) Range
Min: -17680.72   Max: -11.42
Current: -4438.05

-17680.72
-11.42
Net-margin (%) -4452.58
FOLD's Net-margin (%) is ranked higher than
51% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. FOLD: -4452.58 )
FOLD' s 10-Year Net-margin (%) Range
Min: -16427.82   Max: -10.2
Current: -4452.58

-16427.82
-10.2
ROE (%) -123.70
FOLD's ROE (%) is ranked higher than
53% of the 1311 Companies
in the Global Biotechnology industry.

( Industry Median: -30.34 vs. FOLD: -123.70 )
FOLD' s 10-Year ROE (%) Range
Min: -319.35   Max: -9.19
Current: -123.7

-319.35
-9.19
ROA (%) -49.70
FOLD's ROA (%) is ranked higher than
61% of the 1436 Companies
in the Global Biotechnology industry.

( Industry Median: -25.14 vs. FOLD: -49.70 )
FOLD' s 10-Year ROA (%) Range
Min: -3515.77   Max: -6.13
Current: -49.7

-3515.77
-6.13
ROC (Joel Greenblatt) (%) -1991.10
FOLD's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1397 Companies
in the Global Biotechnology industry.

( Industry Median: -359.85 vs. FOLD: -1991.10 )
FOLD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2018.52   Max: -157.76
Current: -1991.1

-2018.52
-157.76
Revenue Growth (3Y)(%) -68.20
FOLD's Revenue Growth (3Y)(%) is ranked higher than
56% of the 775 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. FOLD: -68.20 )
FOLD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -2.6
Current: -68.2

EBITDA Growth (3Y)(%) -12.40
FOLD's EBITDA Growth (3Y)(%) is ranked higher than
70% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. FOLD: -12.40 )
FOLD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 82.8
Current: -12.4

0
82.8
EPS Growth (3Y)(%) -10.10
FOLD's EPS Growth (3Y)(%) is ranked higher than
74% of the 803 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. FOLD: -10.10 )
FOLD' s 10-Year EPS Growth (3Y)(%) Range
Min: -85.2   Max: 59.5
Current: -10.1

-85.2
59.5
» FOLD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

FOLD Guru Trades in Q1 2014

Charles Brandes 48,100 sh (New)
RS Investment Management 2,816,739 sh (+0.69%)
Chuck Royce 313,700 sh (-11.81%)
Jim Simons 121,000 sh (-69.70%)
» More
Q2 2014

FOLD Guru Trades in Q2 2014

George Soros 70,500 sh (New)
Jim Simons Sold Out
Charles Brandes Sold Out
RS Investment Management Sold Out
Chuck Royce 283,700 sh (-9.56%)
» More
Q3 2014

FOLD Guru Trades in Q3 2014

Steven Cohen 195,900 sh (New)
Jim Simons 130,400 sh (New)
Charles Brandes 36,700 sh (New)
Paul Tudor Jones 78,079 sh (New)
RS Investment Management 1,248,215 sh (New)
Chuck Royce Sold Out
George Soros Sold Out
» More
Q4 2014

FOLD Guru Trades in Q4 2014

Louis Moore Bacon 225,000 sh (New)
Jim Simons 508,700 sh (+290.11%)
RS Investment Management 2,850,955 sh (+128.40%)
Paul Tudor Jones 98,522 sh (+26.18%)
Steven Cohen Sold Out
Charles Brandes Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with FOLD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 9.60
FOLD's P/B is ranked higher than
53% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 7.01 vs. FOLD: 9.60 )
FOLD' s 10-Year P/B Range
Min: 0.87   Max: 14.42
Current: 9.6

0.87
14.42
P/S 745.05
FOLD's P/S is ranked lower than
64% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 36.81 vs. FOLD: 745.05 )
FOLD' s 10-Year P/S Range
Min: 0.84   Max: 748.1
Current: 745.05

0.84
748.1
Current Ratio 7.66
FOLD's Current Ratio is ranked higher than
83% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. FOLD: 7.66 )
FOLD' s 10-Year Current Ratio Range
Min: 3.46   Max: 11.32
Current: 7.66

3.46
11.32
Quick Ratio 7.66
FOLD's Quick Ratio is ranked higher than
84% of the 1412 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. FOLD: 7.66 )
FOLD' s 10-Year Quick Ratio Range
Min: 3.46   Max: 11.32
Current: 7.66

3.46
11.32
Days Sales Outstanding 69.09
FOLD's Days Sales Outstanding is ranked higher than
81% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 134.01 vs. FOLD: 69.09 )
FOLD' s 10-Year Days Sales Outstanding Range
Min: 63.94   Max: 1088.97
Current: 69.09

63.94
1088.97

Valuation & Return

vs
industry
vs
history
Price/Net Cash 18.30
FOLD's Price/Net Cash is ranked higher than
66% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 103.40 vs. FOLD: 18.30 )
FOLD' s 10-Year Price/Net Cash Range
Min: 1.39   Max: 12.42
Current: 18.3

1.39
12.42
Price/Net Current Asset Value 18.30
FOLD's Price/Net Current Asset Value is ranked higher than
65% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 42.30 vs. FOLD: 18.30 )
FOLD' s 10-Year Price/Net Current Asset Value Range
Min: 1.35   Max: 23.5
Current: 18.3

1.35
23.5
Price/Tangible Book 13.30
FOLD's Price/Tangible Book is ranked higher than
52% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 10.90 vs. FOLD: 13.30 )
FOLD' s 10-Year Price/Tangible Book Range
Min: 0.96   Max: 54.09
Current: 13.3

0.96
54.09
Price/Median PS Value 49.00
FOLD's Price/Median PS Value is ranked higher than
58% of the 1591 Companies
in the Global Biotechnology industry.

( Industry Median: 3.10 vs. FOLD: 49.00 )
FOLD' s 10-Year Price/Median PS Value Range
Min: 0.11   Max: 33.28
Current: 49

0.11
33.28
Earnings Yield (Greenblatt) -6.90
FOLD's Earnings Yield (Greenblatt) is ranked higher than
64% of the 1389 Companies
in the Global Biotechnology industry.

( Industry Median: -5.30 vs. FOLD: -6.90 )
FOLD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -6.9   Max: 3784.9
Current: -6.9

-6.9
3784.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AM6.Germany,
Amicus Therapeutics Inc incorporated under the laws of the State of Delaware on February 4, 2002. The Company is a Biopharmaceutical Company focused on the discovery, development and commercialization of next-generation medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (LSDs). IT is focused on developing pharmacological chaperones as monotherapy agents (to be used without ERT) and its Chaperone-Advanced Replacement Therapy, or CHART platform of pharmacological chaperones in combination with ERT. Chaperone-Advanced Replacement Therapy, or CHART, platform has been used to develop our next-generation ERTs by co-formulating therapeutic enzymes with our proprietary pharmacological chaperones. It is also developing migalastat HCl as a monotherapy in two Phase 3 global registration studies ("Study 011" and "Study 012") for Fabry patients with genetic mutations that were amenable to this pharmacological chaperone in a cell-based assay. Study 011 is a 24-month study consisting of a 6-month double-blind, placebo-controlled treatment period (Stage 1); a 6-month open-label follow-up period (Stage 2); and a 12-month open-label extension phase. The Company currently operates in one business segment focusing on the development and commercialization of small molecule, orally administered therapies to treat a range of human genetic diseases. Its major competitors include pharmaceutical and biotechnology companies in the U.S. and abroad that have approved therapies or therapies in development for lysosomal storage disorders within our core programs. The Company owns certain trademarks in the U.S. and/or abroad, including A AMICUS THERAPEUTICS & design, AMICUS THERAPEUTICS and CHART.
» More Articles for FOLD

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 09 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 07 2010 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Nov 04 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) Aug 06 2009 
AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q) May 08 2009 
iwillbeback note on FOLD Sep 03 2008 

More From Other Websites
AMICUS THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 13 2015
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day Apr 09 2015
Amicus Therapeutics Honors Fabry Disease Awareness Month and International Pompe Day Apr 09 2015
Amicus Therapeutics Slumps: FOLD Falls 6.8% in Session - Tale of the Tape Mar 23 2015
Amicus to Seek for Migalastat's Approval in the U.S., EU - Analyst Blog Mar 20 2015
Freeport-McMoRan and Guess are big market movers Mar 19 2015
Stocks sold off on Thursday — except for the one sector people are calling a bubble Mar 19 2015
Amicus to seek Fabry disease drug approval Mar 19 2015
Amicus to seek Fabry disease drug approval Mar 19 2015
Amicus Therapeutics (FOLD) Stock Spikes Today Following Accelerated Approval Filing Plan Mar 19 2015
Amicus Up As FDA, EU Green-light Quick Drug Filings Mar 19 2015
Amicus Therapeutics shares rally on news of positive regulatory meetings Mar 19 2015
Amicus Accelerates Approval Filing Plans for Rare Disease Drug Mar 19 2015
Amicus Therapeutics Provides Positive Global Regulatory Updates From EMA and FDA Meetings for Fabry... Mar 19 2015
Amicus Therapeutics Provides Positive Global Regulatory Updates From EMA and FDA Meetings for Fabry... Mar 19 2015
AMICUS THERAPEUTICS INC Financials Mar 12 2015
10-K for Amicus Therapeutics, Inc. Mar 05 2015
Amicus Therapeutics reports 4Q loss Mar 03 2015
Amicus Therapeutics reports 4Q loss Mar 03 2015
Amicus Therapeutics Announces Full-Year 2014 Financial Results and Corporate Updates Mar 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK